PATENT CLAIM ANALYSIS

Application Number: 15876698
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "278000"]

Abstract:
The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Claim (Index 20):
A method for treating a MAGL-mediated disease or disorder in a mammal, which method comprises administering to said mammal a therapeutically effective amount of a compound or pharmaceutically acceptable salt according to  claim 1 , wherein the disorder is selected from the group consisting of a metabolic disorder; a kidney disease; vomiting or emesis; nausea; an eating disorder; neuropathy; burning feet syndrome; a neurodegenerative disorder; a cardiovascular disease; osteoporosis; osteoarthritis; schizophrenia; depression; bipolar disease; tremor; dyskinesia; dystonia; spasticity; Tourette's syndrome; sleep apnea; hearing loss; an eye disease; cachexia; insomnia; meningitis; sleeping sickness; progressive multifocal leukoencephalopathy; De Vivo disease; cerebral edema; cerebral palsy; withdrawal syndrome; traumatic brain injury; non-traumatic brain injury; spinal cord injury; seizures; excitotoxin exposure; ischemia; liver fibrosis, iron overload, cirrhosis of the liver; a lung disorder; a liver disorder, stroke; subarachnoid hemorrhage; intracerebral hemorrhage; vasospasm; AIDS wasting syndrome; renal ischemia; a disorder associated with abnormal cell growth or proliferation; an autoimmune disease; an inflammatory disorder; a disorder of the immune system; post-traumatic stress disorder (PTSD); acute stress disorder; panic disorder; substance-induced anxiety; obsessive-compulsive disorder (OCD); agoraphobia; specific phobia; social phobia; anxiety disorder; attention deficit disorder (ADD); attention deficit hyperactivity disorder (ADHD); Asperger's syndrome; pain; a demyelinating disease; and cognitive impairment.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 86.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15874987', '15221658', '14902324', '15808242', '11127878']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8139335913510937
- 35 USC 102 Novelty (BERT): 0.546788705702054
- Combined Prediction Score: 0.7872191027861897
- Mean Citation Score: 371.852396
- Max Citation Score: 404.64084
- Similarity Product: 259.9958904907894

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test